Catalog # LR5-M5253



#### Synonym

Leucine-rich repeat-containing protein 15,LRRC15,LIB,hLib

## Source

Mouse LRRC15 Protein, Fc Tag(LR5-M5253) is expressed from human 293 cells (HEK293). It contains AA Tyr 22 - Gly 536 (Accession # <u>Q80X72-1</u>). Predicted N-terminus: Tyr 22

## **Molecular Characterization**

LRRC15(Tyr 22 - Gly 536) Fc(Pro 100 - Lys 330) Q80X72-1 P01857

This protein carries a human IgG1 Fc tag at the C-terminus.

The protein has a calculated MW of 83.9 kDa. The protein migrates as 90-95 kDa when calibrated against <u>Star Ribbon Pre-stained Protein Marker</u> under reducing (R) condition (SDS-PAGE) due to glycosylation.

## Endotoxin

Less than 1.0 EU per  $\mu g$  by the LAL method.

# Purity

>90% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

## Formulation

Lyophilized from 0.22  $\mu$ m filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

#### Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

#### Storage


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:


- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.

# **SDS-PAGE**



Mouse LRRC15 Protein, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With <u>Star Ribbon Pre-stained Protein Marker</u>).

# SEC-MALS



The purity of Mouse LRRC15 Protein, Fc Tag (Cat. No. LR5-M5253) is more than 90% and the molecular weight of this protein is around 160-200 kDa verified by SEC-MALS.



## Background

LRRC15 (Leucine-rich repeat-containing protein 15) is also known as LIB and hLib. LRRC15 is highly expressed in a variety of solid tumors. LRRC15 was expressed on stromal fibroblasts in many solid tumors (e.g., breast, head and neck, lung, pancreatic) as well as directly on a subset of cancer cells of mesenchymal





7/23/2024



Catalog # LR5-M5253

origin (e.g., sarcoma, melanoma, glioblastoma). LRRC15 expression was induced by TGF $\beta$  on activated fibroblasts ( $\alpha$ SMA+) and on mesenchymal stem cells. These collective findings suggested LRRC15 as a novel CAF and mesenchymal marker with utility as a therapeutic target for the treatment of cancers with LRRC15-positive stromal desmoplasia or cancers of mesenchymal origin. ABBV-085 is a monomethyl auristatin E (MMAE)-containing antibody–drug conjugate (ADC) directed against LRRC15, and it demonstrated robust preclinical efficacy against LRRC15 stromal-positive/cancer-negative, and LRRC15 cancer-positive models as a monotherapy, or in combination with standard-of-care therapies.

## **Clinical and Translational Updates**



>>> www.acrobiosystems.com

